TAHO Pharmaceuticals Ltd. announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration for TAH3311, marking the first apixaban oral dissolving film to reach this regulatory milestone. The submission represents a significant advancement in anticoagulant therapy for patients with swallowing difficulties, particularly stroke survivors who face substantial challenges with traditional oral medications.
Addressing Critical Unmet Medical Needs
TAH3311 targets a substantial patient population facing serious medical challenges. According to NIH data cited by TAHO, stroke affects more than 15 million people worldwide each year, with over 50% of stroke survivors experiencing dysphagia. This swallowing difficulty places patients at heightened risk for pneumonia, malnutrition, dehydration, and reduced quality of life.
The innovative formulation is designed to improve the delivery of apixaban, a widely used anticoagulant co-developed by BMS and Pfizer under the brand name Eliquis®. Apixaban serves as a direct factor Xa inhibitor approved for clinical use in several thromboembolic disorders, including stroke prevention in non-valvular atrial fibrillation, thromboprophylaxis after hip and knee replacement, and treatment and prevention of deep vein thrombosis or pulmonary embolism.
Proprietary Drug Delivery Technology
TAH3311 is developed using TAHO's proprietary Transepithelial Delivery System (TDS) platform, formulated as an easy-to-use oral dissolving film. This patient-friendly format offers particular benefits for stroke survivors, elderly patients, and others with swallowing difficulties by providing greater convenience and improved treatment adherence.
The TDS platform provides significant advantages over conventional delivery routes, including tailored release profiles ranging from rapid onset to sustained delivery, reduced gastrointestinal side effects, enhanced bioavailability, and simplified administration for patients with compliance challenges. By eliminating the need for swallowing solid dosage forms, TAH3311 helps reduce the risk of choking and aspiration pneumonia.
Regulatory Milestone and Market Strategy
"The NDA submission for TAH3311 reflects our unwavering commitment to addressing unmet patient needs through cutting-edge science," said Dr. Lee, CEO of TAHO Pharmaceuticals. "We are proud to offer a patient-centered solution that has the potential to redefine the standard of care in anticoagulant therapy."
This NDA submission represents a pivotal step toward U.S. market entry, supporting TAHO Pharma's broader vision to improve patient experiences and therapeutic outcomes through novel drug delivery platforms. The company is actively seeking global partnership opportunities to accelerate the product's time to market.
Company Background
Founded in 2010, TAHO Pharma operates as a global small-to-medium enterprise specializing in innovative oral and transdermal drug delivery systems. Through its proprietary TDS platform, TAHO enables efficient transdermal and transmucosal delivery of small-molecule drugs, focusing on scientifically differentiated technology and clinically meaningful solutions to advance patient care and improve quality of life worldwide.
